Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 14/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 14/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 14/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 12/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.49 |
| ▸ | PRKAG3 | Q9UGI9 | 12/20 | 0.49 |
| ▸ | PRKAG2 | Q9UGJ0 | 12/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325340 | 0.88 | PRKAB2 (0.48) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| Hydrochloric Acid SCHEMBL14487854 | 0.87 | PRKAB2 (0.47) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL3104933 | 0.81 | PRKAB2 (0.59) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL10478188 | 0.80 | NR4A2 (0.53) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL13013297 | 0.77 | NR4A2 (0.74) | NR4A2 | |
| SCHEMBL6030723 | 0.77 | KDM4E (0.55) | NR4A2 | |
| SCHEMBL6030601 | 0.77 | NR4A2 (0.51) | GPR84NR4A2IDO1 | |
| SCHEMBL6334125 | 0.77 | NR4A2 (0.74) | NR4A2 | |
| SCHEMBL9215146 | 0.76 | POLB (0.44) | — | |
| SCHEMBL23622947 | 0.74 | F7 (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1242420-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044247-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | PRKAG1 158/4885PRKAA1 369/4885PRKAB1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.